1. Introduction
Over 1.5 million women are diagnosed with and over 0.5 million women die of breast cancer each year. Although breast cancer mortality has declined over the past two decades, breast cancer remains the leading cause of cancer deaths in women aged 20 to 59 years [1, 2]. The adverse impact of breast cancer on quality of life, productivity, and survival, as well as health care costs, have prompted intensive research efforts aimed at the identification of breast cancer prevention methods [3]. Effective chemoprevention strategies with selective estrogen receptor modulators (SERMs), such as tamoxifen, and aromatase inhibitors (AIs), including steroidal inhibitors such as exemestane, and nonsteroidal inhibitors, such as anastrozole and letrozole, have been developed to decrease the risk of both invasive and noninvasive breast cancer [3, 4]. An analysis of 83,399 women at high risk for breast cancer who received SERMs for primary chemoprevention showed a 38% reduction in breast cancer incidence [5]. AIs administered as adjuvant therapy after breast surgery were highly effective in reducing the incidence of breast cancer recurrence in women who are diagnosed with breast cancer [6]. In a randomized exemestane study designed to detect a 65% relative decline in invasive breast cancer, 4,560 eligible postmenopausal women aged 35 or over had at least one of the following risk factors: 60 years or older; Gail 5-year risk score is more than 1.66% (chances in 100 of invasive breast cancer developing within 5 years); prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy, Exemestane decreased the incidence of invasive breast cancers [7]. Available chemoprevention strategies are also related to significant short- and long-term side effects. Guidelines have been developed by the US Preventive Services Task Force (USPSTF) [8, 9] and the American Society of Clinical Oncology (ASCO) [10] regarding the rationale and data-driven, evidence-based use of endocrine therapy for women at high risk for breast cancer. Precision medicines, as well as targeted biotherapeutic agents such as Trastuzumab (Herceptin), offer the opportunity for patient-tailored secondary prevention of breast cancer [11,12]. The discovery of additional effective chemopreventive strategies using chemotherapy drugs, precision medicines, biologics, and natural compounds is a major area of translational research emphasis in contemporary oncology [13].

Our recent drug discovery efforts have focused on a data-driven strategy to identify active chemopreventive...
agents for breast cancer by leveraging an in vivo animal model for carcinogen-induced breast cancer. The purpose of the current review is to summarize the salient features of our studies as well as discuss the insights and lessons learned from biomarker analyses.

2. The 7,12-dimethylbenz(a)anthracene model of breast cancer
Mice treated with the chemical carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) develop mammary gland tumors that morphologically resemble human myoepithelial carcinomas and myoepitheliomas [14]. Adenosquamous carcinomas and ductal carcinomas have also been reported in DMBA-treated mice [15].

The polycyclic aromatic hydrocarbons like DMBA activate the aryl hydrocarbon receptor (AhR), which activates a signal transduction cascade that leads to the formation of the mutagenic epoxide of DMBA via cytochromes P450 enzymes. DNA damage due to this mutagenic epoxide is the proposed driving mechanism of malignant transformation in breast tissue [16]. The DMBA initiates and affects multiple steps of carcinogenesis, starting from the inhibition of differentiation in the early stages and followed by cell cycle disruptions such as upregulation of Cyclin D1 and c-Myc, possibly via nuclear factor-κB and Wnt pathways [17]. Disruptions of intracellular members of cell cycle regulation such as PI3K/mTOR/AKT and PTEN were also seen later in the disease course similar to luminal type human breast cancers [18]. In a series of studies, we have used the DMBA model of breast cancer to evaluate the chemopreventive activity of promising new agents in side by side comparison with the standard antibreast cancer drug paclitaxel. All control mice treated with DMBA developed mammary gland tumors within 16 weeks. The median time for progression-free survival (in other terms time to tumor development) in the standard antibreast cancer drug paclitaxel was 13 weeks for these mice. The standard breast cancer drug paclitaxel preventedor slowed down the development of mammary tumors significantly and more than 25% of rodents remained tumor-free even after 23 weeks. The median time for progression-free survival was increased to 16 weeks in the paclitaxel arm also (Figure 1).

3. Antitumor activity of novel WHI-P131, LFM-A13 and stampidine molecules in DMBA models of breast cancer
In preclinical models, the phosphoramidine derivatives of nucleoside analogs showed anti-tumor activities and emerged as potential anticancer drugs [19]. Stampidine is among these agents and it's an aryl phosphate derivative of stavudine. Its clinical activity was first tested as an anti-HIV agent in preclinical models and also in a phase 1 study[20]. The drug was well-tolerated without dose-limiting toxicities [20]. Stampidine has been shown to act as an epigenetic regulator of gene expression by methylating and silencing the several oncogenic transcription factors[21]. We tested the chemopreventive activity of stampidine in the DMBA model. When co-administered with DMBA, stampidine decreased the number and size of mammary gland tumors that have developed after the DMBA challenge. In addition, the combination of stampidine and paclitaxel synergistically reduced the tumor burden. Another hypothesis-generating point from our study was the demonstration of higher proapoptotic and lower antiapoptotic protein expression in tumors developing in stampidine-treated mice [22]. These results demonstrated that stampidine prevents the development of aggressive breast tumors DMBA challenge. The chemopreventive potency of stampidine was similar to that of paclitaxel as well as two potent kinase inhibitors, WHI-P131 (an inhibitor of HER, Src, and JAK family kinases) [22–25] and LFM-A13 (an inhibitor of TEC and PLK family kinases) [26] (Figures 2–4). These findings illustrate the potential of stampidine as a chemopreventive agent against breast cancer.

In regards to the two lead kinase inhibitors we tested, WHI-P131 was active in the DMBA induced cancer model. The median tumor free-survival was 18 weeks with WHI-P131 with 20% of mice were tumor in the 18th week of DMBA treatment. This tumor-free survival was significantly improved compared to the control arm (P £ 0.001). The antitumor efficacy was similar to that of paclitaxel (P =0.544) (Figures 2 and 3) [25]. We think that the combination of WHI-P131 with conventional chemotherapeutics can further improve the antitumor efficacy of WHI-P131 as a chemopreventive agent.

The other novel agent we evaluated was LFM-A13 (19). In the DMBA model, LFM-A13 significantly increased the survival to 40% compared to 15% in the control arm. The combination of paclitaxel and LFM-A13 further increased the survival rate to 50% in the 25th week. The tumor incidence and also tumor burden were significantly reduced in the LFM-A13 group [26]. LFM-A13 prolonged the tumor-free interval by 2 weeks (15 vs 13 weeks, P = 0.0002) compared to the control arm. 30% of mice treated with LFM-A13 were tumor-free at 20th week demonstrating long-lasting chemoprevention with the agent. The antitumor efficacy was similar to that of paclitaxel and WHI-P131 (Figures 2–4).

Notably, the tumors developing despite chemoprevention with the kinase inhibitors or stampidine were not only small and grew slowly, but they also displayed a uniquely more proapoptotic protein expression profile. Hence, our experimental chemopreventive drugs are capable of preventing the development of aggressive mammary gland tumors with an apoptosis-resistant protein expression profile.
4. Future perspectives

Although the use of tamoxifen and AI’s for secondary prevention have significantly reduced the risk of recurrence in hormone receptor-positive breast cancer after standard first-line therapy (5, 27), many high-risk patient populations (especially those with hormone receptor-negative breast cancer) experience a recurrence. Optimizing secondary prevention with drugs used in the adjuvant and prolonged maintenance therapy settings may contribute to a clinically meaningful improvement of survival outcome. Our data in the DMBA model suggest that stampidine, WHI-P131, and LFM-A13 may be useful as chemopreventive agents and as components for secondary chemoprevention protocols. In the DMBA model, the efficacy of these agents in chemoprevention was similar to that of paclitaxel which is among the most effective breast cancer therapies [27]. We are planning to evaluate their activity in combination with tamoxifen and AIs for secondary prevention considering the potential to inhibit different steps of oncogenesis due to different mechanisms of antitumor action. The enhanced potency observed when these agents were combined with paclitaxel is also deserving of further study [22, 25]. LFM-A13 and WHI-P131 were also tested for activity in MMTV/Neu transgenic HER-2 positive models of breast cancer [23, 28], so their synergism with trastuzumab is another area that warrants further research.

As mentioned earlier, the tumors developing despite chemoprevention with the kinase inhibitors or stampidine displayed a pro-apoptotic protein expression

![Figure 1. Effects of paclitaxel on the proportion of tumor-free survival (a) and macroscopic appearance and histopathological features (b; H&E X200) of DMBA-induced tumors in the mammary glands of mice.](image-url)
profile, which was different from the protein expression profile of aggressive tumors developing in DMBA-treated control mice [22]. Hence, our experimental chemopreventive drugs are capable of preventing the development of aggressive mammary gland tumors with an apoptosis-resistant protein expression profile. It is

![Figure 2](image1.png)

**Figure 2.** Effects of chemoprevention with paclitaxel, LFM-A13, WHI-P131 and stampidine on proportion tumor-free survive in DMBA-challenged mice.

![Figure 3](image2.png)

**Figure 3.** Effects of chemoprevention with paclitaxel, LFM-A13, WHI-P131 and stampidine on the tumor size in DMBA-challenged mice.

|          | Tumor size (cm³) |
|----------|-----------------|
| DMBA     |                 |
| Paclitaxel|                 |
| LFM-A13  |                 |
| WHI-P131 |                 |
| Stampidine|                 |
our working hypothesis that recurrent tumors emerging after chemoprevention with these chemopreventive drugs will, therefore, be substantially more sensitive to available salvage chemotherapy regimens in standard second-line settings. This should contribute to an improved treatment and survival outcome after recurrence.

One of the most important properties of these rationally designed agents is their tolerability which increases their potential to be used in the combinations. All three agents were well tolerated without dose-limiting hematologic, renal and hepatic toxicities in multiple animal studies [26, 28, 29]. Stampidine did not cause any dose-limiting toxicities in a phase 1 study of thirty HIV patients [20]. However, LFM-A13 and WHI-P131 have not been evaluated in human subjects and all three drugs remain to be evaluated in breast cancer patients.

In summary, stampidine, LFM-A13, and WHI-P131 showed potent chemopreventive activity by reducing the development and number of breast tumors and improving the tumor-free survival outcome in breast cancer animal models. Further models and studies testing the synergism of these agents with another chemopreventive agent like tamoxifen and AI's and also the use of these agents for primary chemoprevention in women at high risk for breast cancer would seem warranted.

Acknowledgments
Authors would like to thank all the professors and specialists of our teams for their help, guidance, and contributions.

Disclaimers/ Conflict of interest
This manuscript did not receive any funding. The authors declare no conflict of interest.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2019. CA: A Cancer Journal for Clinicians 2019; 69: 7-34.
2. Dafni U, Tsiourti Z, Alatsathianos I. Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries. Breast Care 2019; 14: 344-353.
3. Bozovic-Spasojevic I, Azambuja E, McCaskill-Stevens W, Dinh P, Cardoso F. Chemoprevention for breast cancer. Cancer Treatment Reviews 2012; 38: 329-339.
4. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R et al. Overview of the main outcomes in breast-cancer prevention trials. The Lancet 2003; 361: 296-300.
5. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. The Lancet (London, England) 2013; 381: 1827-1834.

6. Yang Y, Pan W, Tang X, Wu S, Sun X. A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer. Oncotarget 2017; 8: 48362-48374.

7. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT et al. Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine 2011; 364: 2381-2391.

8. Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M. Medication use for the risk reduction of primary breast cancer in women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Journal of the American Medical Association (JAMA) 2019; 322: 868-886.

9. Force USPST. Medication use to reduce risk of breast cancer: US Preventive Services Task Force Recommendation Statement. Journal of the American Medical Association (JAMA) 2019; 322: 857-867.

10. Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE et al. Use of endocrine therapy for breast cancer risk reduction: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology 2019; 37: 3152-3165.

11. Von Minckwitz G, Procter M, De Azambuja E, Zardavas D, Benyunes M et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. New England Journal of Medicine 2017; 377: 122-131.

12. Loibl S, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B et al. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Annals of Oncology 2017; 28: 497-504.

13. Siddavaram N. Breast Cancer: Current molecular therapeutic targets and new players. Anti-Cancer Agents in Medicinal Chemistry 2017; 17: 152-163.

14. Rehm S. Chemically induced mammary gland adenomyoepitheliomas and myoepithelial carcinomas of mice. Immunohistochemical and ultrastructural features. American Journal of Pathology 1990; 136: 575-584.

15. Siddiqui RA, Harvey KA, Walker C, Altenburg J, Xu Z et al. Characterization of synergistic anti-cancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorigenesis in mice. BMC Cancer 2013; 13: 418. doi: 10.1186/1471-2407-13-418.

16. Russo J, Hu Y-F, Yang X, Russo IH. Developmental, cellular, and molecular basis of human breast cancer. Journal of the National Cancer Institute Monographs 2000; 27: 17-37.

17. Papaconstantinou AD, Shanmugam I, Shan L, Schroeder IS, Qiu C et al. Gene expression profiling in the mammary gland of rats treated with 7,12-dimethylbenz[a]anthracene. International Journal of Cancer 2006; 118: 17-24.

18. Abba MC, Zhong Y, Lee J, Kil H, Lu Y et al. DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations. Oncotarget 2016; 7: 64289-64299.

19. Iyer VV, Griesgraber GW, Radmer MR, McIntee EJ, Wagner CR. Synthesis, in vitro anti-breast cancer activity, and intracellular decomposition of amino acid methyl ester and alkyl amide phosphoramidate monoesters of 3'-azido-3'-deoxythymidine (AZT). Journal of Medicinal Chemistry 2000; 43: 2266-2274.

20. Cahn P, Rolon M, Gun A, Ferrari I, Dibirdik I et al. Preclinical and first-in-human phase I clinical evaluation of stampidine, a potent anti-HIV pharmaceutical drug candidate. Journal of AIDS & Clinical Research 2012; 3: 138. doi:10.4172/2155-6113.1000138

21. Qazi S, Uckun F. Stampidine as a potent epigenetic silencer of host HIV dependency factor genes in HIV-infected cells. Journal of AIDS & Clinical Research 2012; 3: 147. doi:10.4172/2155-6113.1000147

22. Sahin K, Orhan C, Ozercan IH, Tuzcu M, Elibol B et al. Chemopreventive efficacy of stampidine in a murine breast cancer model. Expert Opinion on Therapeutic Targets 2020; 24: 155-162.

23. Dibirdik I, Yiv S, Qazi S, Uckun F. In vivo anti-cancer activity of a liposomal nanoparticle construct of multifunctional tyrosine kinase inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline. Journal of Nanomedicine and Nanotechnology 2010; 101. doi:10.4172/2157-7439.1000101

24. Sudbeck EA, Liu X-P, Narla RK, Mahajan S, Ghosh S et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clinical Cancer Research 1999; 5: 1569-1582.

25. Sahin K, Yabas M, Orhan C, Tuzcu M, Sahin TK et al. Prevention of DMBA-induced mammary gland tumors in mice by a dual-function inhibitor of JAK3 and EGFR receptor tyrosine kinases. Expert Opinion on Therapeutic Targets 2020; 1: 1-9.

26. Sahin K, Tuzcu M, Yabas M, Orhan C, Sahin N et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Investigational New Drugs 2018; 26: 388-395.

27. Perez EA. Paclitaxel in breast cancer. The Oncologist 1998; 3: 373-389.

28. Uckun FM, Dibirdik I, Qazi S, Vassilev A, Ma H et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorganic & Medicinal Chemistry 2007; 15: 800-814.

29. Uckun FM, Ek O, Liu X-P, Chen C-L. In vivo toxicity and pharmacokinetic features of the Janus Kinase 3 Inhibitor WHI-P131 [4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline]. Clinical Cancer Research 1999; 5: 2954-2962.